Which has the lower trailing P/E, BIO or RGEN?

BIO has the lower trailing P/E: BIO trades at 44.71 and RGEN at 239.53. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, BIO or RGEN?

Over the past five years, RGEN grew revenue faster — BIO at a 0.29% CAGR versus RGEN at 9.08%.

Is BIO or RGEN more profitable?

BIO runs the higher net margin — BIO at 8.59% versus RGEN at 5.29%.

How have BIO and RGEN total returns compared?

Over the past 10 years, BIO delivered 8.63% and RGEN delivered 20.13% annualized total return. Past performance doesn't predict future results.

Bio-Rad Laboratories, Inc. (BIO) vs Repligen Corporation (RGEN)

A side-by-side comparison of Bio-Rad Laboratories, Inc. and Repligen Corporation across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

BIO

Bio-Rad Laboratories, Inc.

$9.93B

$368.83HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

RGEN

Repligen Corporation

$9.87B

$174.86HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — BIO vs RGEN

growth of $100 · dividends reinvested · last 10y

BIO +134.6% (+8.9%/yr)RGEN +528.7% (+20.2%/yr)RGEN compounded faster over this window

BIO RGEN

BIO vs RGEN: by the numbers

•BIO is the larger company ($9.93B vs $9.87B market cap).
•BIO trades at the lower trailing earnings multiple (44.71 vs 239.53 P/E), one valuation lens rather than an overall verdict.
•BIO converts more revenue to profit (8.59% vs 5.29% net margin).
•RGEN grew revenue faster over the past five years (9.08% vs 0.29% CAGR).

Metrics side by side

Valuation

Metric	BIO	RGEN
P/E ratio	44.71	239.53
Forward P/E	37.84	84.92
P/S ratio	3.83	12.57
P/B ratio	1.38	4.67
EV / EBITDA	27.75	67.03
FCF yield	3.56%	1.12%

Profitability

Metric	BIO	RGEN
Gross margin	51.90%	51.05%
Operating margin	9.08%	8.32%
Net margin	8.59%	5.29%
ROE	3.10%	1.97%
ROIC	1.54%	1.85%

Growth (annualized)

Metric	BIO	RGEN
Revenue CAGR (5Y)	0.29%	9.08%
EPS CAGR (5Y)	-26.27%	-5.26%
FCF CAGR (5Y)	-9.65%	22.49%
Total return CAGR (5Y)	-12.59%	-6.86%

Frequently asked

Which has the lower trailing P/E, BIO or RGEN?: BIO has the lower trailing P/E: BIO trades at 44.71 and RGEN at 239.53. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, BIO or RGEN?: Over the past five years, RGEN grew revenue faster — BIO at a 0.29% CAGR versus RGEN at 9.08%.
Is BIO or RGEN more profitable?: BIO runs the higher net margin — BIO at 8.59% versus RGEN at 5.29%.
How have BIO and RGEN total returns compared?: Over the past 10 years, BIO delivered 8.63% and RGEN delivered 20.13% annualized total return. Past performance doesn't predict future results.

Go deeper

Full BIO analysis Full RGEN analysis Interactive comparison tool

Dig into the metrics

Bio-Rad Laboratories P/E ratio Repligen P/E ratio Bio-Rad Laboratories ROE Repligen ROE Bio-Rad Laboratories operating margin Repligen operating margin Bio-Rad Laboratories revenue growth Repligen revenue growth Bio-Rad Laboratories free cash flow Repligen free cash flow

Bio-Rad Laboratories & Repligen appear in these rankings

Highest 10-Year Total Return Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.